Journey Clinical raises $3M to allow psychotherapists to prescribe psychedelics

Psychedelics companies are all the rage right now. Compass Pathways is working with the magic mushroom compound psilocybin to treat depression. It’s has raised $290 million in total. Atai Life Sciences — backed by PayPal co-founder Peter Thiel — brought in $258 million from its IPO. In the tech space, this has not gone unnoticed and the same business models that have been used in other platforms for health and wellness startups are coming to psychedelics.

The latest is Journey Clinical, based out of NYC, which has raised a $3 million seed round led by San Francisco VC firm Fifty Years. Also participating were Neo Kuma Ventures, Palo Santo,

Related News

How to Overcome Imposter Syndrome and Launch Your First Product with Confidence

Intel was on the brink of downfall. A twist in the AI race could boost its revival

Incident involving suspect with a knife closes Hwy. 101 in San Jose

Scott Pelley speaks: ‘CBS News is on fire’ and Bari Weiss should be removed

5 vehicles stolen from Alameda County parking garage in Oakland

Video footage shows large groups of people fighting in Oakland